Gilead tack­les a big PhI­II pro­gram for block­buster hope­ful fil­go­tinib

Gilead $GILD has em­barked on an am­bi­tious Phase III pro­gram for fil­go­tinib, one of the most close­ly-watched drugs now in the late-stage pipeline for rheuma­toid arthri­tis.

The sto­ried Gala­pa­gos drug, which had been dumped by Ab­b­Vie on­ly to be quick­ly picked back up in a rich deal with Gilead, is be­ing put through three late-stage stud­ies – dubbed FINCH 1, 2 and 3 – which will test two dos­es in more than 3,000 pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.